title: [Prognostic value of estrogen receptors--ERalpha and ERbeta, in patients with lung cancer].
abstract: CONCLUSIONS
  There are over 150 prognostic factors in lung cancer, which allow to predict the outcome of the disease.Many molecular factors are known to have independent prognostic significance. At present these factors are not routinely used in the clinical practice, but they may play an important role in the future for precise individual prognosis.
  
  
  METHODS
  The study included 122 patients with non-small cell lung cancer.Using immunohistochemistry we examined the expression of estrogen receptors--ERalpha and Erbeta.
  
  
  RESULTS
  The median time of survival depending on the expression of Eralpha was 31 months, while for Erbeta was 73 months.
  
  
  CONCLUSIONS
  Erbeta is a positive prognostic factor in patients with non-small cell lung cancer.
authors.forename: A
authors.initials: A
authors.lastname: Uchikov
authors.forename: I
authors.initials: I
authors.lastname: Dimitrov
authors.forename: B
authors.initials: B
authors.lastname: Hadjiev
authors.forename: G
authors.initials: G
authors.lastname: Prisadov
authors.forename: E
authors.initials: E
authors.lastname: Uchikova
authors.forename: P
authors.initials: P
authors.lastname: Ganchevska
authors.forename: V
authors.initials: V
authors.lastname: Uzunova
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery*; D047628:Estrogen Receptor alpha / Q000032:analysis* / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000032:analysis* / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008168:Lung / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta